The drug name of Porida is aliskirenzumab injection, which is mainly used for the prevention of cardiovascular events and so on, it is not necessary to be injected year-round, and it can be used in accordance with the doctor’s instructions. Aliximab Injection is mainly used for the prevention of cardiovascular events, the treatment of primary hypercholesterolemia and mixed dyslipidemia, but also to reduce the risk of myocardial infarction, unstable angina requiring hospitalization, and stroke in adult patients with confirmed atherosclerotic cardiovascular disease. Aliximab injection is injected subcutaneously, the general starting dose is 75mg once every two weeks, can also be increased to 150mg once every two weeks according to the condition of the drug, there is no hard and fast rule that once the use of this product needs to be injected year-round, the specific duration of the use of the drug should be consulted with the local doctor. Some patients may experience adverse reactions such as liver enzyme abnormalities, urinary tract infections, diarrhea, nasopharyngitis, influenza, myalgia, allergy, etc. It is prohibited for patients who are severely allergic to this product. It is recommended that patients who are unwell go to regular hospitals in a timely manner, follow the doctor’s instructions for symptomatic treatment, and not self-medication.